Gastro Medical News about Hepatitis A

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Monotherapy versus combination therapy for the treatment of chronic hepatitis B
Expert Opinion on Investigational Drugs, 10/26/09

Carey N et al. – Monotherapy with either entecavir or tenofovir is the current preferred option in treatment–naive patients. Combination therapy is appropriate in those with drug–resistant HBV infection, where drug choice is guided by the viral drug–resistance genotype/phenotype. Although combination therapy has been advocated in other patient groups (e.g., those with decompensated cirrhosis and following liver transplantation), there are, as yet, no data to mandate the use of combination therapy in such patients and any perceived benefit must be weighed against increased cost and risk for toxicity.

<< Previous
Fatal Haematuria in a Patient with an Orthotopic Neobladder and...

Next >>
Pancreatic Endocrine Tumors: A Large Single-Center Experience